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ABSTRACT
Objectives: Patients with failed back surgery syndrome (FBSS) and
chronic neuropathic pain experience levels of health-related quality of life
(HRQoL) that are considerably lower than those reported in other areas of
chronic pain. The aim of this article was to quantify the extent to which
reductions in (leg and back) pain and disability over time translate into
improvements in generic HRQoL as measured by the EuroQoL-5D and
SF-36 instruments.
Methods: Using data from the multinational Prospective, Randomized,
Controlled, Multicenter Study of Patients with Failed Back Surgery
Syndrome trial, we explore the relationship between generic HRQoL—
assessed using two instruments often used in clinical trials (i.e., the SF-36
and EuroQol-5D)—and disease-speciﬁc outcome measures (i.e., Oswestry
disability index [ODI], leg and back pain visual analog scale [VAS]) in
neuropathic patients with FBSS.
Results: In our sample of 100 FBSS patients, generic HRQoL was mod-
erately associated with ODI (correlation coefﬁcient: -0.462 to -0.638)
and mildly associated with leg pain VAS (correlation coefﬁcient: -0.165 to
-0.436). The multilevel regression analysis results indicate that functional
ability (as measured by the ODI) is signiﬁcantly associated with HRQoL,
regardless of the generic HRQoL instrument used. On the other hand,
changes over time in leg pain were signiﬁcantly associated with changes in
the EuroQoL-5D and physical component summary scores, but not with
the mental component summary score.
Conclusions: Reduction in leg pain and functional disability is statistically
signiﬁcantly associated with improvements in generic HRQoL. This is the
ﬁrst study to investigate the longitudinal relationship between generic and
disease-speciﬁc HRQoL of neuropathic pain patients with FBSS, using
multinational data.
Keywords: EuroQol-5D, failed back surgery syndrome, neuropathic pain,
quality of life, SF36.
Introduction
Neuropathic pain is a prevalent [1–4] and often underdiagnosed
[5] condition estimated to affect up to 2% to 3% of the general
population [2,5,6]. Back and legs are the most common location
of pain of neuropathic origin [7]. Treatment options vary in
nature and success rate, with the appropriate treatment depend-
ing on individual circumstances. Nonsurgical medical therapy
(that can include a spectrum of rehabilitative and drug therapies)
is often the treatment of choice for the management [2] of indi-
viduals presenting with neuropathic back and leg pain, but a
number of cases will eventually be referred for spinal surgery. Of
these, 10% to 40% will still experience persistent or recurrent
pain [7,8], a condition often referred to as “failed back surgery
syndrome” (FBSS).
Patients with neuropathic pain experience levels of health-
related quality of life (HRQoL) which are considerably lower
than those of chronic heart failure patients [9] and the general
population [10,11]. Increased pain severity is typically associated
with lower levels of HRQoL [12], and high levels of functional
disability [13] in patients with FBSS.
The impact of neuropathic pain (of different origin) on
HRQoL has been the focus of a recent study [13], which
reviewed 52 high-quality published reports on the subject. The
authors found strong evidence that the presence (and severity) of
neuropathic pain are associated with greater impairments in a
number of HRQoL domains. Furthermore, the degree of asso-
ciation between pain and HRQoL decrement was found to
depend on both the type of instrument (generic vs. disease spe-
ciﬁc) used and the HRQoL domain being investigated (physical,
emotional, role, or social functioning). For instance, the authors
found weaker associations between neuropathic pain and mea-
sures of the quality of patients’ social relationships than between
neuropathic pain and measures of other HRQoL domains. Simi-
larly, it was found that associations between pain severity and
pain-speciﬁc measures of HRQoL are generally stronger than
those between pain severity and generic measures of HRQoL.
We report the results of a longitudinal analysis of the asso-
ciation between generic and disease-speciﬁc outcome measures
based on the ﬁrst 6 months follow-up data from the recently
published multinational Prospective, Randomized, Controlled,
Multicenter Study of Patients with Failed Back Surgery Syn-
drome (PROCESS) trial. The PROCESS trial [14] investigated
the addition of spinal cord stimulation (SCS) to conventional
medical management (CMM) in patients with FBSS suffering
from chronic neuropathic back and leg pain [15].
The aim of this article was to quantify the extent to which
reductions in (leg and back) pain and disability (as measured by
the Oswestry disability index [ODI] score) over time translate
into improvements in generic HRQoL as measured by the
EuroQoL-5D [16], and the mental and physical components of
the SF-36 [17] instrument.
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Methods
Study Design, Patient Recruitment, and Data Collection
The design and results of the PROCESS trial have been described
previously in detail [14,15,18]. Brieﬂy, a total of 100 patients
were recruited from 12 centers in Europe, Canada, Australia, and
Israel between April 2003 and June 2005. Eligible subjects were
randomly assigned to CMM alone (n = 48; CMM group) or
CMM with SCS (n = 52; SCS group). Eligibility criteria included
patients 18 years or older suffering from predominant neuro-
pathic pain of radicular origin in the legs (radiating in der-
matomal segments L4 and/or L5 and/or S1) with or without
associated less severe back pain. The intensity of leg pain was at
least 50 mm on a visual analog scale (VAS: 0 equaling no pain, to
100 mm representing the worst possible pain) for at least 6
months after at least one anatomically successful surgery for a
herniated disk. All patients had a documented history of nerve
injury (i.e., root compression by herniated disk, compatible with
the pain complaint). The neuropathic nature of the pain was
conﬁrmed according to the routine clinical practice of each inves-
tigator and included mapping the pain distribution, examining
sensory/motor/reﬂex changes, and EMG. All patients random-
ized to the SCS group underwent a screening trial. Those
experiencing at least 80% overlap of their pain with stimulation-
induced paresthesia and at least 50% leg pain relief received an
implantable neurostimulation system. CMM included oral medi-
cation (i.e., opioids, nonsteroidal antiinﬂammatory drugs, anti-
depressants, anticonvulsants/antiepileptics, and other analgesic
therapies), nerve blocks, epidural corticosteroids, physical and
psychological rehabilitative therapy, and/or chiropractic care. In
either group, the use of intrathecal drug delivery systems and
re-operation were not allowed.
Using case report forms, the investigators prospectively col-
lected detailed information on patients’ baseline age, gender,
prior back operations, and source of major pain. Patients’
HRQoL, pain, and functional capacity were assessed before ran-
domization (baseline), and at 3 and 6 months follow-up.
Instruments aimed at measuring a subject’s HRQoL fall
under one of two categories: generic and disease-speciﬁc instru-
ments [19]. The former attempt to measure the extent to which
an individual’s health status affects a broader set of dimensions
with respect to quality of life, and the generic (as opposed to the
disease-speciﬁc) nature of the instruments makes them suitable
for general use to compare HRQoL status across disease areas
[20]. On the other hand, disease-speciﬁc outcome measures are
designed to focus only on a reduced set of dimensions that are
relevant to the subjects and conditions under study. Typically,
these instruments are more sensitive than their generic counter-
part to minimal changes in health status. The disadvantage is that
they do not facilitate comparison of results across different
disease areas. Examples of generic HRQoL instruments include
the EuroQoL-5D [16] and the SF-36 [17], while examples of
disease-speciﬁc measures in patients with FBSS neuropathic pain
are the ODI [21] and pain indices measured using a VAS
approach.
Generic HRQoL Instruments
For the purposes of the present study, generic HRQoL was
assessed using the physical (PCS) and mental (MCS) component
summary scores of the SF-36 and the EuroQol-5D instrument.
These instruments were completed by the patient the week before
or on the day of the visits (baseline, 3 and 6 months follow-up).
The SF-36 is a general measure of health intended to capture
HRQoL through eight different dimensions, including the ability
to function and complete everyday tasks, perform usual physical
and social activities, as well as capturing aspects relating to an
individual’s mental well-being, such as energy and fatigue. Two
summary measures of physical and mental health can be con-
structed from the eight scales [22]. The PCS and MCS typically
range from 0 to 100 (with 0 = worst possible state), but norm-
based interpretations, in which scores are understood in relation
to typical values (norms) with respect to the US general popula-
tion, are also possible. These two summary scales for the SF-36
are recommended when a general effect (across subscales) in the
physical or mental health domain is expected.
The EuroQol-5D comprises ﬁve questions, each relating to a
different dimension: mobility, self-care, ability to undertake usual
activity, pain/discomfort, and anxiety/depression. Each dimen-
sion has three possible levels of severity: no problems, moderate
problems, and severe problems. Based on their combined
answers to the EuroQol-5D questionnaire, participants can be
classiﬁed as being in one of 243 possible health states (not
including unconsciousness and death). Each of these health states
has an associated score ranging from -0.594 (worse possible
health state) to 1 (perfect health) [16].
Disease-Speciﬁc Outcome Measures
During 4 days preceding each study visit, the patients were asked
to record their level of pain, measured using a VAS (0 equivalent
to no pain, and 100 equivalent to worst possible pain), three
times per day separately for back and leg pain [23]. The week
before or on the day of the follow-up visit, the patients completed
the ODI (version 2) [21] questionnaire, to assess pain-related
disability. The ODI questionnaire covers 10 domains of func-
tional ability (e.g., personal care, lifting, traveling, sex life,
walking, social life), each having six possible levels of severity
ranging from zero (no limitation) to ﬁve (greatest possible limi-
tation). The respondent is asked to select the severity level that
best describes his/her perception for each of the 10 domains. The
percentage of disability (i.e., total ODI score) is obtained by
adding up the domain-related points, dividing the total by 50,
and multiplying the result by 100. A score between 0 and 20%
indicates minimal disability, 21% to 40% is moderate disability,
41% to 60% reﬂects severe disability, 61% to 80% indicates
level of pain that impinges on all aspects of the patient’s life
requiring positive intervention, and ﬁnally scores between 81%
and 100% indicate patients who are bed bound [21].
Statistical Analysis
A three-stage approach was followed to analyze the HRQoL data
in the PROCESS trial.
Assessing changes from baseline. First, we looked at the trend
over time of generic and disease-speciﬁc outcome measures, plot-
ting their mean (and 95% conﬁdence interval) values at baseline
and at each follow-up time. In addition, we estimated—for each
HRQoL instrument—the change from baseline values at 3 and 6
months follow-up. To address the risk of “regression to the
mean” fallacy [24], changes from baseline were estimated using
an analysis of covariance approach [25].
The ﬁrst stage of the analysis was used to assess whether or
not there was any practical justiﬁcation (other than the theoreti-
cal one referring to a repeated measure design), to a more sophis-
ticated statistical analysis, than a change from baseline.
Statistically signiﬁcant changes from baseline at 3 and 6 months
follow-up would, for instance, indicate the presence of a strong
correlation over time, suggesting that the EuroQol-5D of a given
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subject observed at follow-up can be predicted by the
EuroQol-5D value reported by the same subject at baseline.
Assessing between instrument correlation. The second stage of
the statistical analysis included scatter plots of individual patient
scores at baseline and estimation of relevant pair-wise Pearson
correlation coefﬁcients to assess the pair-wise association
between generic HRQoL and pain (leg and back) or disability
(ODI) measures. Although the ﬁrst stage of the analysis assessed
the within-measure correlation over time, the second stage was
used to deﬁne the extent of between-outcome correlation at a
given time point.
The presence of such a correlation structure would then
justify the use of a regression framework to include several
predictors of outcome at once, while accounting for the observed
between- and within-HRQoL instrument correlation.
Multilevel modeling for longitudinal data analysis. Such a
regression framework takes the name of multilevel (also known
as hierarchical or repeated measures or random effects) modeling
[26,27], and the advantages deriving from its use for the analysis
of HRQoL are well recognized [28,29]. The basic structure of a
multilevel regression model for longitudinal data can be written
as follows:
y t u u tij ij i i ij ij= + + + + +β β ε0 1 0 1. . . (1)
where y represents the value of the dependent variable (e.g.,
EuroQoL-5D) of patient i at time j. The intercept term (b0)
represents the mean value of the outcome variable across all
patients at baseline, while the coefﬁcient (b1) captures the average
change in y at each measurement occasion, denoted by the vari-
able tij.
The model allows subject-speciﬁc HRQoL (at baseline and at
each follow-up point) to depart (at random) from the overall
mean trend represented by (b0 + b1tij). The extent to which a
given subject’s HRQoL departs from the overall mean at a
particular time point is governed by the “random” part of the
model (hence, the name “random effects” model) represented
by (u0i + u1itij + eij). The term u0i captures the subject-speciﬁc
random departure from the overall mean outcome, while the
random term u1i indicates the subject-speciﬁc departure from the
average change in y at each measurement occasion (tij). Finally, eij
represents the between-subjects variability. The total variability
in the data is therefore decomposed as between and within-
subjects variability. More elaborated model speciﬁcations, like
the one implemented in this article, can also include a series of
subject-speciﬁc characteristics (e.g., age, gender).
By appropriately accounting for both the between- andwithin-
subjects’ correlation, the use of a multilevel modeling framework
facilitates the correct estimation of the standard errors for the
regression parameters in the model and correct quantiﬁcation of
the P-values for hypothesis testing. Furthermore, the inclusion of
several explanatory variables within the multilevel regression
model helps quantify the contribution of a given predictor (e.g.,
leg pain) to the observed outcome, conditional on a set of other
factors (e.g., age, clinical status, functional disability).
Thus, the third step of the analysis consisted of a series of
multilevel regression models developed with the aim to quantify
the extent to which the dynamics of generic HRQoL measures
can be predicted by disease-speciﬁc measures such as pain (back
and leg) and disability (ODI) scores, after controlling for patient-
speciﬁc baseline characteristics (i.e., age, gender, number of pre-
vious back surgeries, time since last surgery, location of the pain).
The set of predictors included in the analysis was not selected on
statistical grounds, but based on evidence from published litera-
ture, integrated by the expert clinical, health economics, statisti-
cal, and epidemiological opinion of the coauthors. The rationale
for this is twofold. First, the “best” prediction model on statis-
tical grounds may lack clinical meaning, and second, there are a
number of factors that are known to be important predictors
regardless of their statistical signiﬁcance in the data set at hand.
Two different speciﬁcations of the multilevel model were
compared: one in which the HRQoL was assumed to follow a
linear trend over time, and the secondwhere theHRQoL followed
a quadratic (i.e., nonlinear) trend. The latter was achieved by
including an additional term (i.e., β2 2tij ) in Equation (1), to capture
a possible nonlinear behavior in the dynamics of the HRQoL over
time at patient level. Model comparison and model selection were
carried out using the Bayesian information criteria (BIC) statistics.
The latter can be viewed as a measure that combines model ﬁt and
model complexity, through which alternative models can be com-
pared and selected. The model with the lowest BIC should be
selected. All analyses were carried out in the statistical software
STATA 10.0 [30], and the multilevel regression models were
carried out using the STATA command—xtmixed—and the
STATA user written package gllamm [31,32].
Results
Outcomes at Baseline
Baseline characteristics of the study sample are reported in
Table 1. The patients were on average 50 years old, 50% of them
having had more than one back surgery (mean number of previ-
ous back surgeries: 1.75), their last surgery taking place approxi-
mately 4.7 years before recruitment into the trial. The location of
leg pain was mostly unilateral (65%). The study sample reported
average levels of leg and back pain (on a VAS 0–100 mm scale) of
75 and 50, respectively, and a mean ODI score of 56, which
indicates severe disability. Average generic HRQoL scores were:
EuroQol-5D: 0.16 (on a -0.594 to 1 scale) and PCS: 27.4 and
MCS: 39.5 (both on a scale 0–100).
Stage 1: Trends in Outcomes
Figure 1 shows the mean scores for EuroQol-5D (Fig. 1a), SF-36
physical (PCS, Fig. 1b) and mental (MCS, Fig. 1c) component
summary measures, ODI (Fig. 1d), leg (Fig. 1e) and back (Fig. 1f)
pain at baseline, and at 3 and 6 months of follow-up. Our sample
reported improvements in each of the HRQoL and disease-
speciﬁc measures over the ﬁrst 6 months of the study period, and
these improvements were all statistically signiﬁcant with the
exception of the changes in back pain and MCS.
Table 1 Baseline characteristics (n = 100)
Male, n (%) 51 (51)
Age in years, mean (SD) 50.3 (10)
Time since last surgery, years (SD) 4.7 (5)
>1 Surgery, n (%) 50 (50)
Unilateral leg pain, n (%) 65 (65)
Back pain VAS, mean (SD) 49.8 (24)
Leg pain VAS, mean (SD) 74.7 (13)
Disability (ODI), mean (SD) 56.3 (14)
Generic HRQoL, mean (SD)
PCS 27.4 (6)
MCS 39.5 (12)
EuroQol-5D 0.16 (0.3)
HRQoL, health-related quality of life; MCS, mental health summary score (SF-36); ODI,
Oswestry disability index; PCS, physical health summary score (SF-36); VAS, visual analog
scale.
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Stage 2: Association between Generic HRQoL and
Disease-Speciﬁc Measures at Baseline
Figure 2 depicts the matrix of univariate pair-wise scatter plots,
and reports the Pearson correlation coefﬁcients for the generic
(i.e., EuroQol-5D, PCS, and MCS) and disease-speciﬁc (i.e., ODI,
leg and back pain) measures of HRQoL at baseline. Consistent
with the results of the review by Jensen et al. [13], we found a
varying degree of pair-wise correlation between HRQoL mea-
sures, which suggests that the explanatory power of the variables
(a)
(b)
(c)
(d)
(e)
(f)
Figure 1 Raw mean (95% conﬁdence interval) score for health-related quality of life (HRQoL), using the EuroQol-5D and physical and mental component scores
(PCS and MCS, respectively) of the Short-Form 36 ([SF-36], disability, [Oswestry disability index,ODI), and leg and back pain (visual analog scale,VAS) over time.Note:
Higher scores in the EuroQol-5D, PCS, and MCS indicate better HRQoL. Higher values in the pain (VAS) and disability (ODI) measures indicate worse status.
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(leg and back) pain and functional disability might differ depend-
ing on the generic HRQoL measures to which they are being
related. Figure 2 suggests that greater levels of leg pain are asso-
ciated with lower levels of generic HRQoL, as measured by
the EuroQol-5D (correlation coefﬁcients vs. leg pain: -0.436
[P < 0.05]). Furthermore, MCS (vs. leg pain: -0.215; vs. back
pain: -0.095) and PCS (vs. leg pain: -0.165; back pain: -0.118)
displayed a negative (although not statistically signiﬁcant) asso-
ciation with leg and back pain. Finally, ODI showed a statisti-
cally signiﬁcantly negative correlation with all generic HRQoL
measures: EuroQol-5D (correlation coefﬁcient: -0.638
[P < 0.05]), MCS (correlation coefﬁcient: -0.301 [P < 0.05]), and
PCS (pair-wise correlation: -0.462 [P < 0.05]), indicating that
lower functional disability is associated with higher generic
HRQoL. Incidentally, ODI was also signiﬁcantly correlated with
leg (pair-wise correlation: 0.466 [P < 0.05]) and back pain (pair-
wise correlation: 0.340 [P < 0.05]).
Stage 3: Predictors of Outcomes
The third stage of our analysis used multilevel regression to
assess the joint relationship between generic HRQoL measures
and a set of predictors, which included disease-speciﬁc outcomes
such as ODI and (leg and back) pain VAS scores. Table 2 reports
the results of the multilevel regression analyses relating generic
HRQoL (i.e., EuroQol-5D, PCS, and MCS) measures to pain,
disability levels, and patients’ baseline characteristics. The results
of the EuroQol-5D regression model indicate that, on average,
higher leg pain and functional disability are signiﬁcantly associ-
ated with lower EuroQol-5D (coefﬁcient for leg pain: -0.039;
coefﬁcient for ODI: -0.069 [all P < 0.001]). Thus, at the margin,
if the other factors such as patient age and number of previous
back operations are held constant, a 1 point increase in leg pain
(ODI) corresponds to a 0.039 (0.069) reduction in EuroQoL-5D.
Repeated observations over time on the same individual were
strongly correlated; therefore, the baseline outcome score is a
strong predictor in our model (coefﬁcient for baseline EuroQol-
5D: 0.529 [P < 0.001]). The same set of predictors was found to
be statistically signiﬁcant in the PCS model (coefﬁcient for leg
pain: -0.079; coefﬁcient for ODI: -0.089; coefﬁcient for baseline
PCS: 0.721 [all P < 0.001]). In the MCS model, two signiﬁcant
predictors were found: ODI (coefﬁcient: -0.137 [P < 0.001]) and
baseline MCS score (coefﬁcient 0.815 [P < 0.001]). None of the
other baseline characteristics were found to be statistically asso-
ciated with the trend of the patients’ HRQoL over the ﬁrst 6
months of the study period. Statistical comparison between a
model with a linear trend and a model with a quadratic trend of
the HRQoL over time suggests that the best model ﬁt was
EuroQol-5D
score
Mental
Health
Summary
Physical
Health
Summary
Oswestry
Disability
Index
Mean
leg
pain
Mean
back
pain
0.357*
0.299*
-0.638*
-0.436*
-0.098 -0.095 -0.118 0.340* 0.371*
0.466*
-0.165-0.215 
-0.301* -0.462*
-0.376* 
Figure 2 Pair-wise correlation (and scatter plot) at baseline between EuroQol-5D, physical and mental component scores (PCS and MCS, respectively) of the
Short-Form 36 (SF-36), Oswestry disability index (ODI), and back and leg pain (visual analog scale,VAS). Note:The graph combines a scatter plot and a correlation
matrix. The former provides a visual representation of the correlation between the variables, whereas the latter gives an estimate of the pair-wise correlation
coefﬁcient.A star next to the reported pair-wise correlation coefﬁcient indicates statistical signiﬁcance at the 5% level or better.
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achieved by the linear time trend (because this model had the
lowest BIC); therefore, the results presented here were based on
the linear trend model. Standardized residual plots for each of the
three regression analyses conﬁrmed adequate model ﬁt (ﬁgures
available on request).
Discussion
We carried out the longitudinal analysis of the 6-month
follow-up (generic HRQoL and disease-speciﬁc outcome mea-
sures) data from the recently completed multinational PROCESS
trial, which compared the addition of SCS to CMM versus CMM
alone in patients with chronic neuropathic pain secondary to
FBSS [15].
Consistent with the ﬁndings of Jensen et al. [13], we found
that the degree of association between patient’s levels of pain,
disability, and generic HRQoL depends on both the HRQoL
measure and the dimensions of HRQoL being investigated. Our
results indicate that functional ability (as measured by the ODI)
is signiﬁcantly associated with HRQoL, regardless of the generic
HRQoL instrument used. On the other hand, changes over time
in leg pain were signiﬁcantly associated with changes in the
EuroQoL-5D and PCS scores, but not with the MCS score. A
possible explanation for the latter rests on the characteristics of
the study population. The high levels of pain reported by patients
with chronic neuropathic conditions secondary to FBSS have an
undeniable impact on these patients’ physical well-being, limiting
their ability to carry out tasks, such as lifting or moving objects,
climbing stairs or walking, and self-care. Previous evidence sug-
gests that individuals’ mental well-being tends to adjust to
chronic disease conditions [33], which might be at the source of
our ﬁnding regarding the apparent lack of a statistically signiﬁ-
cant link between leg pain and MCS.
The patients enrolled in the PROCESS trial had lower levels
of HRQoL—on each of the eight domains of the SF-36—than
those recruited in other studies in this clinical area [10,12]. The
mean EuroQol-5D reported by subjects in the PROCESS trial at
baseline (0.16) is identical to that reported by the group experi-
encing the most severe level of pain (i.e., VAS: 7–10) in the survey
published by McDermott et al. [12].
Our results suggest there is some level of: 1) pair-wise corre-
lation between HRQoL measures at a given time point (see
Methods, Stage 2; and 2) correlation over time within each
HRQoL instrument (see Methods, Stage 1). The absolute mag-
nitude of the correlation coefﬁcients though was small (i.e., when
expressed as R2 one would only explain a proportion of the
variance on one outcome on the basis of knowing the other), and
this may be because of the fact that each of them is being
considered independently from the others. The third stage of our
analysis used multilevel regression to assess the joint relationship
between generic HRQoL measures and a set of predictors, which
included disease-speciﬁc outcomes such as ODI and (leg and
back) pain VAS scores.
We did not ﬁnd changes in back pain to be signiﬁcantly
associated with changes in the EuroQoL-5D and SF-36 physical
and mental summary scores. This may be explained by: 1) the
characteristics of the PROCESS study population, where the
predominant pain was leg pain; 2) the multifactorial nature of
back pain; and 3) the smaller impact of the interventions on back
pain.
Our study found that a number of the baseline patients’
characteristics included in the model, such as age, gender, and
location of pain, were not statistically signiﬁcant predictors of
their generic HRQoL. This result is somewhat surprising and
may be a simple artifact of the relatively small sample size and
the carefully selected nature of the population in the PROCESS
trial, which resulted in a homogenous mix of patient character-
istics compared to a more broadly drawn sample. This result
should therefore be interpreted with caution, and we recommend
further research into the identiﬁcation and selection of predictors
of future HRQoL in neuropathic pain patients with FBSS. A
further note of caution relates to the interpretation of the multi-
Table 2 Multilevel regression analyses of HRQoL scores on patient characteristics, pain, and disability
EuroQol-5D PCS MCS
Coefﬁcient P-value Coefﬁcient P-value Coefﬁcient P-value
Age 0.0007 0.571 0.0031 0.909 -0.0188 0.705
Sex (female = 0, male = 1) 0.0449 0.104 -0.3951 0.471 1.2731 0.212
Number of previous back surgeries
Two 0.0029 0.922 0.1145 0.846 0.6005 0.581
Three 0.0051 0.909 -1.0663 0.230 -0.2692 0.870
Four or more 0.0016 0.976 -0.2668 0.813 0.7644 0.714
Time from last back surgery (years) 0.0025 0.652 0.0883 0.438 -0.0850 0.687
Bilateral leg pain (unilateral = 0, bilateral = 1) -0.0188 0.507 -0.1384 0.807 -1.1425 0.276
Back pain (VAS) 0.0004 0.430 -0.0006 0.950 -0.0145 0.453
Leg pain (VAS) -0.0039 <0.001 -0.0785 <0.001 -0.0309 0.201
ODI -0.0069 <0.001 -0.0893 <0.001 -0.1367 <0.001
Baseline HRQoL score 0.5290 <0.001 0.7207 <0.001 0.8155 <0.001
Visit 0.0090 0.070 0.1165 0.292 0.010 0.963
Intercept 0.6907 <0.001 18.6689 <0.001 19.0933 <0.001
Bayesian information criteria (BIC)
For models reported here 33 1760 2124
For models with quadratic trend (not reported) 51 1773 2136
Note: These results allow prediction of the mean HRQoL score at a given follow-up time between baseline and 6 months for a hypothetical patient based on the set of covariates included
in the model. For instance, at 6 months follow-up, the mean physical component summary score of an individual with the following characteristics: male, aged 40 at recruitment in the trial, with
three previous back surgeries, unilateral leg pain, who had the last back surgery 2.5 years before, is expected to be, on average , 29.23—which is obtained as: 18.67 [intercept] + (0.1165 ¥ 6)
[coefﬁcient for visit: ¥6 months follow-up] + (0.7207 ¥ 27.44) [coefﬁcient for baseline PCS ¥mean baseline PCS] + (-0.3951 ¥ 1) (coefﬁcient for male ¥ dummy for male) +
[0.0031 ¥ (50.39 - 40)] [coefﬁcient for age ¥ departure from the mean age in the trial, i.e., (50.39 - 40) years] + (-1.0663 ¥ 1) (coefﬁcient for three previous back surgeries ¥ dummy for three
previous back surgeries] + (-0.1384 ¥ 0) [coefﬁcient for unilateral leg pain ¥ dummy for unilateral) + (0.0883 ¥ 2.5) (coefﬁcient for time since last back surgery ¥ number of years since last back
surgery] + (-0.0785 ¥ 53.43) [coefﬁcient for leg pain ¥mean leg pain at 6 months] + (-0.0006 ¥ 46.07) (coefﬁcient for back pain ¥mean back pain at 6 months] + (-0.0893 ¥ 50.21) (coefﬁcient
for ODI ¥mean ODI at 6 months].
HRQoL, health-related quality of life; MCS, mental health summary score (SF-36); ODI, Oswestry disability index; PCS, physical health summary score (SF-36); VAS, visual analog scale.
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level model results presented here. The EuroQol-5D regression
model indicated that, on average, higher leg pain and functional
disability are signiﬁcantly associated with lower EuroQol-5D
(coefﬁcient for leg pain: -0.039; coefﬁcient for ODI: -0.069 [all
P < 0.001]). These results are valid in the context of the study
sample, and extrapolation beyond the characteristics of the study
sample may lead to biased predictions in terms of improvements
in HRQoL following a reduction in pain and/or disability. Fur-
thermore, any extrapolation exercise will need to take into
account the underlying correlation structure between the predic-
tors of outcome (regardless of their statistical signiﬁcance).
Most of the research investigating the relationship between
generic and disease-speciﬁc outcome measures in neuropathic
chronic pain patients comes from either cross-sectional studies
(i.e., where relationships are estimated at a given point in time)
[10,12], or has focused on slightly different patient groups. We
argue that to assess how generic HRQoL measures (e.g., EQ-5D,
SF36) respond to changes in health status, as measured by the
disease-speciﬁc instruments (e.g., pain, ODI score), requires a
longitudinal study design (which is designed to take into account
their statistical association over time).
To our knowledge, the only report which has assessed the
longitudinal relationship between generic and disease-speciﬁc
outcome measures in this clinical area, albeit focusing on a
slightly different patient group, comes from a case series study
conducted in Finland. Häkkinen et al. [34] studied the HRQoL
of a sample of 145 lumbar disk surgery patients compared to the
general population, assessing the relationships between HRQoL
15D instrument [35] and other outcome measures—such as ODI,
short depression inventory (SDI) pain, trunk muscle strength,
and mobility of the spine—at 2 and 14 months after surgery. The
authors found that the 15D, Oswestry, and SDI scores remained
unchanged during the follow-up, while the improvements in the
spine mobility and trunk muscle strength were signiﬁcant. Fur-
thermore, HRQoL, as measured by the 15D instrument, was
associated with age, pain, Oswestry, and SDI indices, but not
with objective measures of physical function.
Another study conducted in Sweden [10] assessed the psycho-
metric properties of the SF-36 and the Nottingham Health Proﬁle
(NHP) in patients with peripheral neuropathic pain of multiple
origin. The cross-sectional analysis of the 126 subjects recruited
in the study found: 1) SF-36 and NHP to be consistent with each
other, showing important correlation between items referring to
the same dimension of HRQoL; and 2) demonstrated the burden
of illness of this health condition comparing these instruments
against the values reported by the general population.
A recently reported large, observational, cross-sectional
survey of 602 neuropathic pain patients recruited from general
practitioners in 6 European countries [12] has produced further
evidence of the burden of neuropathic pain. The authors col-
lected data on the brief pain inventory instrument and the
EuroQol-5D, as well as patients’ demographics, treatment infor-
mation, and frequency of physician visits. Pain severity was
found to be associated signiﬁcantly with poorer EuroQol-5D
scores, greater disruption of employment status, and more fre-
quent physician visits. Finally, a small number of other studies
conducted in this patient population used disease-speciﬁc
outcome measures of outcomes only (e.g., McGill pain question-
naire, sickness impact proﬁle) [36].
The generalizability (from one country to another) of the
ﬁndings of single-country studies is often limited by factors such
as the health-care system in which patients are treated, the soci-
etal set of values with respect to a given health condition, etc.
[37]. It has been shown that self-reported HRQoL for speciﬁc
groups of patients can vary not only between countries [38,39],
but also within the same country [40]. In this sense, by enrolling
individuals from different countries and different settings, analy-
ses of quality-of-life data collected alongside multinational trials
can be perceived to offer results that are more “generalizable.”
To the authors’ knowledge, this is the ﬁrst longitudinal analy-
sis of HRQoL data carried out alongside a multinational ran-
domized, controlled, clinical trial to explore the relationship
between generic HRQoL and disease-speciﬁc outcome measures
in the chronic neuropathic pain population with FBSS. This study
brings new evidence in support of the hypothesis that pain and
disability in patients with FBSS have a strong association with
reduced levels of HRQoL. Interventions aimed at reducing pain
and disability in FBSS patients are therefore expected to bring
considerable HRQoL improvements, thus reducing the burden of
disease in this clinical area.
Establishing the relationship between disease-speciﬁc out-
comes (such as pain and functional ability) and generic HRQoL
will aid in efﬁcient data collection strategies in future research
studies, minimizing the burden of data collection on patients.
The development of such tools would also help address the
never-ending problem of missing data, arising from dropout, in
longitudinal studies. Further studies in pain are needed to explore
the link between disease-speciﬁc outcomes and HRQoL.
Conclusions
Generic HRQoL (EuroQoL-5D and SF-36) was found to have
some degree of association with disease-speciﬁc outcome mea-
sures (leg pain VAS and ODI) in selected patients with chronic
neuropathic pain secondary to FBSS. Further studies in chronic
neuropathic pain populations are needed to explore the link
between disease-speciﬁc outcomes and HRQoL.
Source of ﬁnancial support: This study was funded by Medtronic, Inc. The
authors had full, nonrestricted access to the data. The funding source had
no role in the analysis or interpretation of the data. The conclusions of the
study are entirely those of authors. The publication of study results was
not contingent on the sponsor’s approval or censorship of the article.
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